{"preliminary_commentary":{"by_channel":{"x_thread":5,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ATALANTE","nct_id":"NCT02891824","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=atalante-nct02891824. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ATALANTE","arms":[{"description":"The placebo arm:\n\nPlacebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression","label":"Arm A: Placebo + Avastin + platinum-based chemotherapy","type":"PLACEBO_COMPARATOR"},{"description":"The atezolizumab arm:\n\nAtezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression\n\n.","label":"Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Hoffmann-La Roche"],"completion_date":{"date":"2024-02-22","type":"ACTUAL"},"conditions":["Ovarian Cancer"],"enrollment":{"count":614,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"atezolizumab + avastin + platinum-based chemotherapy","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"placebo + avastin + platinum-based chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2025-02-11","lead_sponsor":"ARCAGY/ GINECO GROUP","official_title":"A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-10-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1","timeFrame":"An average of 19 months"}],"references":[{"citation":"Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez Garcia J, Petru E, Kocian R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier E, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29.","pmid":"37643382","type":"DERIVED"}],"start_date":{"date":"2016-09-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","url":"https://clinicaltrials.gov/study/NCT02891824"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/atalante-nct02891824"}